BIIB022 is an intravenously administered inhibitor of IGF-1R. It is under development by Biogen Idec.
Definition from NCI Drug Dictionary: BIIB022 is a recombinant, human monoclonal antibody directed against the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. Anti-IGF-1R recombinant monoclonal antibody BIIB022 binds to membrane-bound IGF-1R, preventing binding of the ligand IGF-1 and the subsequent triggering of the PI3K/Akt signaling pathway; inhibition of this survival signaling pathway may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis. The activation of IGF-1R, a tyrosine kinase and a member of the insulin receptor family, stimulates cell proliferation, enables oncogenic transformation, and suppresses apoptosis; IGF-1R signaling has been highly implicated in tumorigenesis and metastasis.
This drug was evaluated in the following Phase I trial which is now closed.
Preliminary results were presented at the 2010 ASCO meeting (link to abstract). The most common (10% of pts) related adverse events (AEs) were headache, fatigue, and nausea. Most related AEs were Grade 2. [Grade goes from 1 (least severe) to 5 (most severe).]
It is expected that this drug will advance to Phase II trials.